Angiotensin-(1-7) Cardiovascular Effects in Aging

Description

Aging is an independent risk factor for developing hypertension and cardiovascular disease; however, the mechanisms underlying age-related cardiovascular disease remain poorly understood. One hallmark of aging is an increase in sympathetic nervous system activity, which can decrease the number and/or sensitivity of β2 adrenergic receptors to reduce dilation of blood vessels and increase blood pressure. Identifying new targets to restore vascular β2 adrenergic receptor signaling may help reduce cardiovascular risk in aging. This study will test the hypothesis that angiotensin-(1-7), a protective hormone of the renin-angiotensin system, can reduce cardiovascular sympathetic outflow and blood pressure and improve endothelial function in older healthy humans.

Conditions

Aging

Talk to us

Study Overview

On this page

Study Details

Study overview

Aging is an independent risk factor for developing hypertension and cardiovascular disease; however, the mechanisms underlying age-related cardiovascular disease remain poorly understood. One hallmark of aging is an increase in sympathetic nervous system activity, which can decrease the number and/or sensitivity of β2 adrenergic receptors to reduce dilation of blood vessels and increase blood pressure. Identifying new targets to restore vascular β2 adrenergic receptor signaling may help reduce cardiovascular risk in aging. This study will test the hypothesis that angiotensin-(1-7), a protective hormone of the renin-angiotensin system, can reduce cardiovascular sympathetic outflow and blood pressure and improve endothelial function in older healthy humans.

Angiotensin-(1-7) Cardiovascular Effects in Aging

Angiotensin-(1-7) Cardiovascular Effects in Aging

Condition
Aging
Intervention / Treatment

-

Contacts and Locations

Hershey

Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States, 17033

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Men and women of all races and ethnicities
  • * Capable of giving informed consent
  • * Fluent in written and spoken English
  • * Age 65-80 years
  • * Body mass index (BMI) between 18.5 and 30 kg/m2
  • * Normotensive defined as seated blood pressure \<130/80 mmHg and without hypertensive medications
  • * Satisfactory history and physical exam
  • * Age \< 65 or \> 80 years
  • * Women who are pregnant, nursing, or taking hormone replacement therapy
  • * Decisional impairment
  • * Prisoners
  • * Current or recent (less than 6 months) recreational drug history or excessive alcohol abuse history (greater than 14 drinks per week)
  • * Current smokers
  • * Highly trained athletes
  • * Evidence of type I or type II diabetes (fasting glucose \> 126 mg/dL or use of anti-diabetic medications)
  • * Hypertension or history of serious cardiovascular disease (e.g., myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g., cerebral hemorrhage, stroke, transient ischemic attack).
  • * History or presence of immunological or hematological disorders
  • * Impaired hepatic function \[aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels \>2 times upper limit of normal range\]
  • * Impaired renal function (serum creatinine \>2.0 mg/dl)
  • * Anemia
  • * Taking drugs known to influence sympathetic activity (e.g. serotonin-norepinephrine reuptake inhibitors, norepinephrine transporter inhibitors, stimulants).
  • * Treatment with anticoagulants (e.g. warfarin)
  • * Treatment with chronic systemic glucocorticoid therapy (\>7 consecutive days in 1 month in the 1-month preceding the study)
  • * Treatment with any investigational drug in the 1-month preceding the study
  • * Known allergy or contraindication to angiotensin converting enzyme inhibitors or angiotensin receptor blockers, both of which increase endogenous angiotensin-(1-7) levels as part of their mechanism of action
  • * Inability to give, or withdraw, informed consent

Ages Eligible for Study

65 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Milton S. Hershey Medical Center,

Amy Arnold, PhD, PRINCIPAL_INVESTIGATOR, Pennsylvania State University College of Medicine

Study Record Dates

2025-12